Bio-Path Holdings Aktie
WKN DE: A2PB4K / ISIN: US09057N3008
19.12.2024 13:41:00
|
Why Bio-Path Is Rising In Pre-market?
(RTTNews) - Bio-Path Holdings (BPTH) reported that results from preclinical studies of BP1001-A for obesity demonstrated enhanced insulin sensitivity, confirming BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. BP1001-A downregulates growth factor receptor-bound protein 2 expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients.
Bio-Path has initiated animal studies to confirm the efficacy of BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. If successful, the company plans initiating a first-in-human Phase 1 clinical trial in 2025.
Shares of Bio-Path are up 65% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Path Holdings Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |